+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antibody Discovery Services and Platforms Market (3rd Edition) by Service Offered, by Antibody Discovery Method, by Nature of Antibody Generated and by Key Geographies: Industry Trends and Global Forecasts, 2020-2030

  • ID: 5157422
  • Report
  • July 2020
  • Region: Global
  • 503 Pages
  • Roots Analysis

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3E Bioventures Capital
  • Ballast Point Ventures
  • Eisai
  • In-Cell-Art
  • NeoBiotechnologies
  • Sino Biological
  • MORE

Overview

With close to 80 monoclonal antibodies approved till date, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become an important part of the biopharmaceutical industry. In fact, they are presently estimated to constitute the largest class of biologics in the industry. Examples of recently approved monoclonal antibody products include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). These molecules have high target specificities and favorable safety profiles. Further, given the success of monoclonal antibodies, research on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, has also gained traction.

The development of such biologics is inherently complex, and many drug developers are now seeking to optimize R&D efficiency and affiliated costs. As a result, innovator companies are outsourcing most of their discovery-stage operations to specialty contract research organizations (CROs). Modern CROs are known to offer a plethora of advanced technologies to cater to the evolving needs. Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to drug/therapy developers. Therefore, as the demand for antibody based therapeutic/diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to rise steadily in the foreseen future.

Scope of the Report

The “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics.

In addition to other elements, it includes:

  • An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).
  • An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company’s employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.
  • Elaborate profiles of antibody discovery service providers. Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook.
  • A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
  • A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2020.  
  • Elaborate profiles of antibody discovery platform providers. Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology/platform(s) offered and an informed future outlook.
  • An assessment of antibody discovery service and platform providers’ capability in different regions, based on a number of relevant parameters. For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered. On the other hand, the service providers have been evaluated based on the type(s) of service offered.
  • An analysis of the partnerships that have been established in this domain since 2015, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and/or commercialization agreements, clinical trial agreements, and other relevant deals.
  • An analysis of the investments made in this domain, during the period between 2016 and 2020 (till April), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery.
  • Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues. Each profile features a brief overview of the drug, the type of antibody discovery method it employs and the annual historical sales of the product.
  • A case study on antibody humanization and affinity maturation, including a list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends in this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • A brief discussion on the imminent opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Tracey Mullen (Chief Executive Officer, Abveris Antibody)
  • Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences)
  • Mark Kubik (Chief Business Officer, AvantGen)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Ignacio Pino (Chief Executive Officer and President, CDI Laboratories)
  • Jeng Her (Chief Executive Officer, AP Biosciences)
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Aaron Sato (former Chief Scientific Officer, LakePharma)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3E Bioventures Capital
  • Ballast Point Ventures
  • Eisai
  • In-Cell-Art
  • NeoBiotechnologies
  • Sino Biological
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies

4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies

5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Type of Antibody Discovery Method
5.2.6. Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size
5.2.7. Analysis by Animal Model Used
5.2.8. Analysis by Type of Antibody Discovered
5.2.9. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.10. Analysis by Purpose of Antibody Discovery
5.2.11. Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based in North America
6.4.2. Antibody Discovery Service Providers based in Europe
6.4.3. Antibody Discovery Service Providers based in Asia Pacific

7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Aragen Bioscience (A GVK BIO Company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Distributed Bio
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services
7.2.3.3. Recent Developments and Future Outlook
7.2.4. Integral Molecular
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services
7.2.4.3. Recent Developments and Future Outlook
7.2.5. LakePharma
7.2.5.1. Company Overview
7.2.5.2. Antibody Discovery Services
7.2.5.3. Recent Developments and Future Outlook
7.3. Antibody Discovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services
7.3.1.4. Recent Developments and Future Outlook
7.3.2. ImmunoPrecise Antibodies
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Antibody Discovery Services
7.3.2.4. Recent Developments and Future Outlook
7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services
7.3.3.3. Recent Developments and Future Outlook
7.4. Antibody Discovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services
7.4.1.3. Recent Developments and Future Outlook
7.4.2. Viva Biotech
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Antibody Discovery Services
7.4.2.4. Recent Developments and Future Outlook
7.4.3. WuXi Biologics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services
7.4.3.4. Recent Developments and Future Outlook

8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers: List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies and Platforms
8.3.1. Analysis by Type of Antibody Discovery Method
8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability

9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Key Parameters
9.4. Technology Competitiveness Analysis: Antibody Discovery Platforms
9.4.1 Competitiveness Analysis: Library Based Antibody Discovery Platforms
9.4.2. Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
9.4.3. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
9.4.4. Competitiveness Analysis: Other Antibody Discovery Platforms

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. ImmunoPrecise Antibodies
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Portfolio of Antibody Discovery Platforms
10.2.3.1. Abthena™
10.2.3.2. B cell Select™
10.2.3.3. DeepDisplay™
10.2.3.4. ModiFuse™
10.2.3.5. ModiPhage™
10.2.3.6. ModiSelect™
10.2.3.7. ModiTune™
10.2.4. Recent Developments and Future Outlook
10.3. Harbour BioMed
10.3.1. Company Overview
10.3.2. Portfolio of Antibody Discovery Platforms
10.3.2.1. H2L2 Platform
10.3.2.2. HCAb Platform
10.3.3. Recent Developments and Future Outlook
10.4. Kymab
10.4.1. Company Overview
10.4.2. Portfolio of Antibody Discovery Platforms
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook
10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Portfolio of Antibody Discovery Platforms
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developments and Future Outlook
10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Portfolio of Antibody Discovery Platforms
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook

11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1 Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in North America
11.3.2. Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Europe
11.3.3. Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Asia-Pacific
11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in North America
11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Europe
11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Asia-Pacific
11.5. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by the Type of Company (Service / Platform Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Partnership and Type of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
12.3.9. Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount Invested
13.3.5. Most Active Investors: Analysis by Number of Funding Instances
13.3.6. Regional Analysis by Amount Invested
13.4. Concluding Remarks

14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market, 2020-2030
14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
14.4.1. Antibody Discovery Services Market for Antigen Designing, 2020-2030
14.4.2. Antibody Discovery Services Market for Hit Generation, 2020-2030
14.4.3. Antibody Discovery Services Market for Lead Selection, 2020-2030
14.4.4. Antibody Discovery Services Market for Lead Optimization, 2020-2030
14.4.5. Antibody Discovery Services Market for Lead Characterization, 2020-2030
14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030
14.5.1. Antibody Discovery Services Market for Phage Display, 2020-2030
14.5.2. Antibody Discovery Services Market for Yeast Display, 2020-2030
14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2020-2030
14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
14.5.6. Antibody Discovery Services Market for Other Methods, 2020-2030
14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030
14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
14.6.2. Antibody Discovery Services Market for Human Antibodies, 2020-2030
14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2020-2030
14.7. Global Antibody Discovery Services Market: Distribution by Region, 2020-2030
14.7.1. Antibody Discovery Services Market in North America, 2020-2030
14.7.2. Antibody Discovery Services Market in Europe, 2020-2030
14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region

15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms Market, 2020-2030
15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030
15.5.1. Antibody Discovery Platforms Market in North America, 2020-2030
15.5.2. Antibody Discovery Platforms Market in Europe, 2020-2030
15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030

16. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
16.1. Chapter Overview
16.2. Humira® (Adalimumab)
16.2.1. Drug Overview
16.2.2. Discovery Process and Method
16.2.3. Historical Sales
16.3. Keytruda® (Pembrolizumab)
16.3.1. Drug Overview
16.3.2. Discovery Process and Method
16.3.3. Historical Sales
16.4. Herceptin® (Trastuzumab)
16.4.1. Drug Overview
16.4.2. Discovery Process and Method
16.4.3. Historical Sales
16.5. Avastin® (Bevacizumab)
16.5.1. Drug Overview
16.5.2. Discovery Process and Method
16.5.3. Historical Sales
16.6. Rituxan® (Rituximab)
16.6.1. Drug Overview
16.6.2. Discovery Process and Method
16.6.3. Historical Sales

17. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
17.1. Importance of Antibody Humanization and Affinity Maturation
17.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
17.3. Antibody Humanization: Publication Analysis
17.3.1. Publication Analysis: Year-Wise Trend
17.3.2. Publication Analysis: Key Journals
17.3.3. Publication Analysis: Distribution by Animal Model Used
17.3.4. Publication Analysis: Distribution by Method Used for Humanization
17.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

18. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
18.1. Chapter Overview
18.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
18.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
18.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
18.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
18.6. Growing Market Opportunities in the Asia-Pacific Region
18.7. Expected Increase in Number of Collaborations and Licensing Activity
18.8 Concluding Remarks

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Abveris Antibody
19.2.1. Company Snapshot
19.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)
19.3. Nidus Biosciences
19.3.1. Company Snapshot
19.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
19.4. AvantGen
19.4.1. Company Snapshot
19.4.2. Mark Kubik, Chief Business Officer(Q1 2020)
19.5. Single Cell Technology
19.5.1. Company Snapshot
19.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
19.6. Distributed Bio
19.6.1. Company Snapshot
19.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)
19.7. AbCellera
19.7.1. Company Snapshot
19.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)
19.8. AbGenics Life Sciences
19.8.1. Company Snapshot
19.8.2. Sanjiban K Banerjee, Director (Q2 2018)
19.9. CDI Laboratories
19.9.1. Company Snapshot
19.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)
19.10. AP Biosciences
19.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)
19.11. YUMAB
19.11.1. Company Snapshot
19.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
19.12. Antibody Solutions
19.12.1. Company Snapshot
19.12.2. Debra Valsamis, Business Development Associate (Q2 2017)
19.13. Ligand Pharmaceuticals
19.13.1. Company Snapshot
19.13.2. Christel Iffland, Vice President (Q2 2017)
19.14. LakePharma
19.14.1. Company Snapshot
19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

20. CONCLUDING REMARKS
20.1. Chapter Overview
20.2. Key Takeaways

21. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
  • 3E Bioventures Capital
  • 3SBio
  • A*STAR's Genome Institute of Singapore
  • Ab Initio Biotherapeutics
  • Ab Studio
  • ABBA Therapeutics
  • AbBioSci
  • AbbVie
  • Abcam
  • AbCellera
  • Abcentra
  • AbCheck
  • Abeome
  • AbGenics Life Sciences
  • ABL Bio
  • Ablexis
  • Abpro
  • Absolute Antibody
  • AbVision
  • Abwiz Bio
  • Abzena
  • Abzyme Therapeutics
  • AC Immune
  • Accel
  • Acceleron Pharma
  • Accurus Biosciences
  • Achaogen
  • ACYTE Biotech
  • Adagene
  • Adaptate Biotherapeutics
  • Adimab
  • Aduro Biotech
  • Advantech
  • Advantech Capital
  • AffinityImmuno
  • Affitech
  • Agency for Science, Technology and Research
  • Agenus
  • AIMM Therapeutics
  • Aimmune Therapeutics
  • Aisling Capital
  • Akeagen
  • Akeso Biopharma
  • Aldevron
  • Alector
  • Alligator Bioscience
  • Allogene Therapeutics
  • Alloy Therapeutics
  • Ally Bridge Group
  • Alta Partners
  • Alzheimer's Drug Discovery Foundation
  • Amgen
  • Amgen Ventures
  • Ampersand Capital Partners
  • AnaImmune
  • Analytics Engine
  • AnaptysBio
  • Andera Partners
  • Antagene
  • Antibody Design Labs
  • Antibody Solutions
  • Antiverse
  • AP Biosciences
  • Apexigen
  • Aptevo Therapeutics
  • Aquila BioMedical
  • Aquila Capital
  • Aquilo Capital Management
  • Aragen Bioscience
  • ARCH Venture Partners
  • Arcus Biosciences
  • argenx
  • Aridis Pharmaceuticals
  • Aro Biotherapeutics
  • Aronora
  • Arsanis
  • Artizan Biosciences
  • Assistant Secretary for Preparedness and Response
  • Astellas Pharma
  • AstraZeneca
  • aTen Therapeutics
  • Atreca
  • Autolus Therapeutics
  • AvantGen
  • AVIC Capital
  • AxioMx
  • Ballast Point Ventures
  • Bayer
  • BBI Group
  • BeiGene
  • Beijing Shijilongxin Investment
  • Berkeley Lights
  • Betta Pharmaceuticals
  • Bhami’s Research Laboratory
  • Bharat Innovation Fund
  • Bill & Melinda Gates Foundation
  • BioAtla
  • Biocytogen
  • BioDiscovery
  • BioDuro
  • Biogen
  • BioInvent
  • Biomatics Capital
  • BioNTech
  • Bio-Rad Laboratories
  • BioSavita
  • Biosion
  • Biotechnology Value Fund
  • Biotecnol
  • BIOTEM
  • Biotheus
  • Birchmere Labs
  • Bird Rock Bio
  • Blue Sky BioServices
  • bluebird bio
  • Boehringer Ingelheim
  • Boston Children's Hospital
  • Boxer Capital
  • Brain Canada
  • Bristol-Myers Squibb
  • Broteio Pharma
  • Burrage Capital
  • CALIXAR
  • CANbridge
  • Cancer Prevention and Research Institute of Texas
  • Carterra
  • Catalent Biologics
  • CBC Group
  • CCB Capital
  • CDH Investments
  • CDI Laboratories
  • Celexion
  • Celgene
  • Cell Signaling Technology
  • Celsius Therapeutics
  • Centers for Disease Control and Prevention (CDC)
  • Charles River Laboratories
  • ChemBio Discovery Solutions
  • Chemical Abstracts Service (CAS)
  • ChemPartner
  • Chia Tai Tianqing Pharmaceutical
  • China Life Investment Holding
  • China Life Private Equity Investment
  • ChinaEquity Group (CEG)
  • Chiome Bioscience
  • Chugai Pharmabody Research
  • Chugai Pharmaceutical
  • Cilag
  • Citryll
  • City of Hope
  • Columbia University Irving Medical Center
  • Compass Therapeutics
  • Cormorant Asset Management
  • Corvidia Therapeutics
  • Cosmo Bio
  • Cowen Healthcare Investments
  • Cowin Venture Capital
  • CR-CP Life Science Fund
  • Creative Biolabs
  • Creative Biostructure
  • Creative Diagnostics
  • Crescendo Biologics
  • Crystal Bioscience
  • CSL Behring
  • CStone Pharmaceuticals
  • CureVac
  • CUSABIO TECHNOLOGY
  • DAFNA Capital Management
  • Daiichi Sankyo
  • Dako
  • Dana-Farber Cancer Institute
  • DCVC (Data Collective)
  • DaTaMabs
  • Decheng Capital
  • Defense Advanced Research Projects Agency (DARPA)
  • Delian Capital
  • Denali Therapeutics
  • Dianomi Therapeutics
  • Diatheva
  • Digital Proteomics
  • Distributed Bio
  • DJS Antibodies
  • Early Drug Development Group (E2DG)
  • EcoR1 Capital
  • Efung Capital
  • Eight Roads
  • Eisai
  • Eli Lilly and Company
  • Elpis Biopharmaceuticals
  • Emergent BioSolutions
  • Enterprise Singapore
  • Enthera
  • Entos Pharmaceuticals
  • EpimAb Biotherapeutics
  • Epiphron Capital Group
  • Eureka Therapeutics
  • European Investment Bank
  • European Molecular Biology Laboratory (EMBL)
  • Eurostars
  • Evotec
  • Exelixis
  • Exiris
  • exonbio
  • FairJourney Biologics
  • Faron Pharmaceuticals
  • FCMI Parent
  • Ferring Pharmaceuticals
  • Five Prime Therapeutics
  • Flagship Pioneering
  • Flanders Innovation and Entrepreneurship
  • Floodgate
  • ForteBio
  • Fortune Capital Services
  • Forty Seven
  • F-Prime Capital
  • Fred Hutchinson Cancer Research Center
  • FREJOY Investment Management
  • Fusion Antibodies
  • Fusion Pharmaceuticals
  • G&P Biosciences
  • G.N. Tech Venture
  • Genagon Therapeutics
  • Genedata Biologics
  • GeneFrontier
  • Geneious Biologics
  • General Atlantic
  • Genmab
  • Genor Biopharma
  • GenScript
  • GHO Capital
  • GIC
  • GigaGen
  • Gilead Sciences
  • Glenmark Pharmaceuticals
  • Glythera
  • Gopher Asset Management
  • GP Healthcare Capital
  • Grenoble Alpes University Hospital
  • Grifols
  • GlaxoSmithKline
  • Gustave Roussy
  • GV20 Oncotherapy
  • H3 Biomedicine
  • Harbour BioMed
  • Harpoon Therapeutics
  • HD Biosciences
  • Henlix Biotech
  • Heptares Therapeutics
  • Hercules Capital
  • Heritas Capital Management
  • HiFiBiO Therapeutics
  • Hillhouse Capital Group
  • HJB
  • Hony Capital
  • HOPU Investments
  • Huaxing Growth Capital
  • Hummingbird Bioscience
  • i2 Pharmaceuticals
  • Ibex Biosciences
  • Icosagen
  • IDG Capital
  • IFB Hamburg
  • IGEM Therapeutics
  • I-Mab Biopharma
  • iMetabolic Biopharma
  • Immatics Biotechnologies
  • Immune Biosolutions
  • Immune Pharmaceuticals
  • ImmunoChina Pharmaceuticals
  • ImmunoGenes
  • Immunome
  • Immunomic Therapeutics
  • ImmunoPrecise Antibodies
  • ImmunoQure
  • In-Cell-Art
  • Incyte
  • Indivumed
  • Inhibrx
  • Innate Pharma
  • Innogene Kalbiotech
  • Innovate UK
  • Innovative Targeting Solutions
  • Innovent Biologics
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Institute for Research in Biomedicine
  • Intarcia Therapeutics
  • IntelliCyt
  • Integral Molecular
  • Invenra
  • Invest Northern Ireland
  • IONTAS
  • IP Group
  • Isogenica
  • Italian National Institute of Health
  • ITBMed
  • iTeos Therapeutics
  • Janssen Biotech
  • JDRF T1D Fund
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson Innovation
  • Jounce Therapeutics
  • Juno Therapeutics
  • Just Biotherapeutics (Acquired by Evotec)
  • Kadmon
  • Kaken Pharmaceutical
  • Keystone Capital Partners
  • Kite Pharma
  • Kodiak Sciences
  • Kymab
  • LakePharma
  • LAMPIRE Biological Laboratories
  • Lava Therapeutics
  • Leading Biology
  • Legend Capital
  • Legend Star
  • Leidos Biomedical Research
  • LEO Pharma
  • LG Chem
  • Life Science Partners
  • LifeArc
  • Ligand Pharmaceuticals
  • Light Chain Bioscience
  • Lilly Ventures
  • Lineage Biosciences (Acquired by AbCellera)
  • Linear Venture
  • Lipum
  • Lonza
  • Lundbeck
  • LYFE Capital
  • MAB Discovery
  • Mablytics
  • Mabpharm
  • MabSpace Biosciences
  • MabVax Therapeutics
  • MacroGenics
  • Magenta Therapeutics
  • Maine Biotechnology Services
  • Malin
  • Massachusetts General Hospital
  • MassBiologics
  • Maverick Therapeutics
  • MD Anderson Cancer Center
  • MedAbome
  • MedImmune
  • MEMO Therapeutics
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merus
  • MI-mAbs
  • Mirae Asset Financial Group
  • Mitsubishi Tanabe Pharma
  • Mitsubishi UFJ Capital
  • ModiQuest Research
  • Molcure
  • Molecular Devices
  • Molecular Templates
  • MolMed
  • Moradec
  • MorphoSys
  • Mount Sinai Health System
  • MPM Capital
  • MRL Ventures Fund
  • MSM Protein Technologies
  • Mycenax Biotech
  • National Cancer Institute
  • National Centre for Biomolecular Research
  • National Center for Research and Development
  • National Heart, Lung and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • National Institute of General Medical Sciences
  • NanoString Technologies
  • NB Health Laboratory
  • NBE-Therapeutics
  • NeoBiotechnologies
  • NeoClone
  • Neon Therapeutics
  • neoX Biotech
  • Nest.Bio Ventures
  • Neurimmune
  • New World TMT
  • Nidus BioSciences
  • NJCTTQ
  • Nkarta Therapeutics
  • North Coast Biologics
  • NovaRock Biotherapeutics
  • Novartis
  • Novo Nordisk
  • Numab Therapeutics
  • NYU Langone Health
  • Oceanpine Capital
  • Olympic Protein Technologies
  • Oncothyreon
  • Ono Pharmaceutical
  • Open Monoclonal Technology
  • OrbiMed Advisors
  • OREGA Biotech
  • ORI Healthcare Fund
  • OriGene Technologies
  • OriMAbs
  • Ossianix
  • Oxford Sciences Innovation
  • Paladin Capital Group
  • Pandion Therapeutics
  • Panoply Bio
  • Pediatric Brain Tumor Consortium
  • Penn Medicine
  • Pennsylvania Industrial Development Authority
  • Pfizer
  • pH Pharma
  • Phanes Therapeutics
  • PharmAbcine
  • PharmaLegacy
  • Pierre Fabre
  • Polaris Partners
  • Potenza Therapeutics
  • PPF Group
  • Precision Antibody
  • Protein Alternatives (PROALT)
  • ProteoGenix
  • ProtTech
  • Proxima Ventures
  • Purdue Pharma
  • Pure Biologics
  • PX'Therapeutics
  • Qianhai Qinzhi Capital
  • Qiming Venture Partners
  • QIMR Berghofer Medical Research Institute
  • QoolAbs
  • Quan Funds
  • Quebec Consortium for Drug Discovery (CQDM)
  • Queen's University
  • Redalpine Venture Partners
  • Redmile Group
  • Regeneron Pharmaceuticals
  • Regione Lazio
  • Resonant Therapeutics
  • Retrogenix
  • Revolve Biotechnologies
  • Rezolute
  • Rhenman & Partners Asset Management
  • Roche
  • RubrYc Therapeutics
  • Rx Biosciences
  • SAB Biotherapeutics
  • Samsara BioCapital
  • Samsara Networks
  • San Diego Biomedical Research Institute
  • Sanofi
  • Sanyou Biopharmaceuticals
  • SARomics Biostructures
  • Schroder Adveq
  • Sea Lane Biotechnologies
  • SEEDS Capital
  • Selecxine
  • Sequoia Capital China
  • Serum Institute of India
  • Sevion Therapeutics
  • Shanghai Junshi Biosciences
  • Shenyang Sunshine Pharmaceuticals
  • Shenzhen GTJA Investment Group
  • Shenzhen Hepalink Pharmaceutical
  • Shenzhen Innovation Capital Investment
  • Shire
  • Shilps Sciences
  • Sichenzia Ross Ference
  • Sichuan Kelun-Biotech Biopharmaceutical
  • Siegfried Holding
  • Silverton Partners
  • Simcere Pharmaceutical
  • Simon Fraser University
  • Single Cell Technology
  • Sino Biological
  • Sinobioway
  • SK Holdings
  • Sofinnova Partners
  • Sorrento Therapeutics
  • SOTIO
  • South Dakota Equity Partners
  • Specifica
  • Standford University
  • State Development & Investment
  • State of Wisconsin Investment Board (SWIB)
  • Straterx
  • Summit Partners
  • Surface Oncology
  • Surveyor Capital
  • Sutro Biopharma
  • Suzhou Oriza Holdings
  • Syd Labs
  • Symphogen
  • Synbio Technologies
  • Syngene
  • TA Associates
  • Takeda
  • Talem Therapeutics
  • Tanabe Research Laboratories
  • Tasly Biopharmaceuticals
  • Technical University of Denmark
  • Telix Pharmaceuticals
  • Temasek Holdings
  • TeneoBio
  • TESARO
  • TetraGenetics
  • Teva Pharmaceutical Industries
  • TG Therapeutics
  • The University of Texas MD Anderson Cancer Center
  • The Wistar Institute
  • Theraclone Sciences
  • Theranyx
  • Thermo Fisher Scientific
  • Thiel Capital
  • Third Point Ventures
  • Third Venture Biopharma
  • Tasgen Bio-Tech
  • ThromboGenics
  • Tizona Therapeutics
  • Tmunity Therapeutics
  • Torch Biosciences
  • TRACON Pharmaceuticals
  • Transcenta Holding
  • Transgene
  • TRIANNI
  • Tri-Institutional Therapeutics Discovery Institute
  • Tsinghua University
  • Twist Bioscience
  • UK Innovation & Science Seed Fund
  • University College London
  • University of Navarra
  • University of Oxford
  • University of Southampton
  • University of Surrey
  • University of Technology Sydney
  • University of Texas
  • U-Protein Express
  • US Department of Defense
  • Vaccinex
  • Vall d'Hebron Institute of Oncology
  • Valneva
  • Velabs Therapeutics
  • venBio
  • Vertex Holdings
  • VI Ventures
  • Vinnova
  • Vir Biotechnology
  • Visterra
  • Vital Venture Capital
  • Viva Biotech
  • Voyager Therapeutics
  • Washington University School of Medicine
  • Watson Investments
  • Wellington Management
  • Wisconsin Alumni Research Foundation
  • Woodford Investment Management
  • Woodford Patient Capital Trust
  • WuXi AppTec
  • Wuxi Biologics
  • XBiotech
  • xCella Biosciences
  • Xencor
  • XOMA
  • Yale Cancer Center
  • Yinuoke
  • YUMAB
  • Yurogen Biosystems
  • Zai Lab
  • Zebra Biologics
  • Zhejiang Teruisi Pharmaceutical
  • Zheshang Venture Capital
  • Zumutor Biologics
  • Zurich Cantonal Bank
  • Zydus Cadila
  • Zymeworks
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll